Zobrazeno 1 - 10
of 3 160
pro vyhledávání: '"disproportionality"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Congenital anomalies of the external ear can have a significant impact on a child’s development and quality of life. While genetic factors play a crucial role in the etiology of these anomalies, environmental factors such as drug exposure
Externí odkaz:
https://doaj.org/article/18bb469fc2df4ba9865b5d2b0d5dc07e
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Lacosamide was the first approved third-generation antiepileptic drug. However, real-world data regarding its adverse cardiac reactions in large samples still need to be completed. We evaluated the cardiac safety profile of lacosamide using
Externí odkaz:
https://doaj.org/article/10b697f3e8a740bfb7eb0a303f5d17e6
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundProton pump inhibitors (PPIs) are effective treatments for acid-related disorders but may pose tumor risks with long-term use. Current research on PPI-associated tumor adverse events (TAEs) is limited and inconclusive. This study aims to co
Externí odkaz:
https://doaj.org/article/44af80abe221417cbca31223d1352cfd
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThis study aims to investigate adverse drug reaction signals associated with coagulopathies through data mining using the Adverse Event Reporting System (FAERS) of the US Food and Drug Administration. Prompt identification of high-risk drug
Externí odkaz:
https://doaj.org/article/24680ba70c3d4c24874b881a7d896791
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionRetinal vein occlusion (RVO) often causes irreversible visual impairment, making early prevention crucial. This study aims to identify associations between different medications and RVO and provide information for clinical practice.Method
Externí odkaz:
https://doaj.org/article/e061c4e571c94c8c99d46e2c48f989c9
Publikováno v:
Cancer Medicine, Vol 13, Iss 23, Pp n/a-n/a (2024)
ABSTRACT Background Mogamulizumab is a monoclonal antibody targeting the C‐C chemokine receptor 4, used to treat T‐cell malignancies such as cutaneous T‐cell lymphoma, adult T‐cell leukemia/lymphoma, and peripheral T‐cell lymphoma. However,
Externí odkaz:
https://doaj.org/article/4d7e7f4c5afd4778abc4722ab972b54e
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundNeuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening adverse drug reaction. This study aims to identify the most prevalent drugs associated with the risk of NMS according to the United States Food and Drug Adminis
Externí odkaz:
https://doaj.org/article/c618d0fd64da46599adb86ba00aca5e0
Autor:
Jordi Mestres
Publikováno v:
Frontiers in Drug Safety and Regulation, Vol 4 (2024)
IntroductionCurrent individual case safety report (ICSR) databases contain almost 56 million unique spontaneous declarations of drug-event associations by health professionals but also by patients themselves. These databases have become a useful sour
Externí odkaz:
https://doaj.org/article/d1a320332a23470aa0d762fd5fcc6a08
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Disproportionality analyses are the most-commonly used study design used in the post-marketing phase to detect suspected adverse drug reactions in individual case safety reports. Recent years have witnessed an exponential increase in published articl
Externí odkaz:
https://doaj.org/article/27f51b0d95244949849ad51aaf5b244b
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundPlecanatide is a selective gastrointestinal peptide used for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Given its widespread use, understanding the long-term safety of plec
Externí odkaz:
https://doaj.org/article/d0231914f62e4861ab42105906080b88